Shalay, khubaro ka socota FDA (Maamulka Cunnada iyo Dawooyinka) ayaa baadhay kiiska IQOS, nidaamka tubaakada kulul ee caanka ah ee Philip Morris. Iyo sida ugu badan ee loo sheego in FDA aysan ka labalabeyn inay go'aan ka gaarto goobta ay ku dhawaaqday in Philip Morris uusan si buuxda u muujin in qalabkiisu uu hoos u dhigay khatarta cudurka.
PHILIP MORRIS IQOS wax ka dhimi kara khatari ma jirto!
Haddii ra'yiga FDA ay tahay talobixin oo keliya oo aan qasab ahayn in su'aal la gelin doono suuqgeynta suurtagalka ah ee alaabta dhowr bilood gudahood, xaqiiqadu waxay ahaanaysaa in gabagabada la muujiyay ay yihiin kuwo taban. Runtii, sida laga soo xigtay guddiga la-talinta ee Wakaaladda Caafimaadka Federaalka (FDA) ee la kulmay shalay Philip Morris International waa in aan loo oggolaan in ay sheegto in aaladdeeda tubaakada kulul ee iQOS ay yarayn karto khatarta cudurrada sigaarka la xiriira.
Guddigani waxa ay tixgelinayaan in Philip Morris uusan si buuxda u muujin in qalabkiisu uu yareeyo khatarta cudurrada. Waxa uu sidoo kale diiday sheegashada ah in isticmaalka qalabkan uu ka khatar yar yahay sii wadida sigaarka.
Guddidu, si kastaba ha ahaatee, waxay aqbashay sheegashada Philip Morris ee ah in iQOS ay hoos u dhigto isticmaaleyaasheeda soo-gaadhista kiimikooyinka waxyeelada leh ama khatarta ah ee sigaarka cabba ee gabi ahaanba joojiya sigaarka. Laakiin shirkadda tubaakada ma caddayn in hoos u dhigista soo-gaadhistani ay keentay hab macquul ah oo macquul ah oo la qiyaasi karo oo hoos u dhac weyn ku yimid dhimashada.
Dhanka kale, ku dhawaaqistani waxay saameyn xoog leh ku yeelatay suuqa saamiyada Philip Morris kaas oo lumiyay in ka badan 6% ka hor inta aan la tirtirin qayb ka mid ah khasaarahiisa iyo dhajinta hoos u dhaca 2,1% ilaa 108,28 dollars 17:47 p.m. GMT ee Wall Street. Si loo arko haddii bilaha soo socda qalabku uu ka heli doono oggolaansho suuqgeyn gudaha Maraykanka iyo in kale.
source : Borsorama
